With placebo there was no change in HbA1c while a decrease of 0.6 % , ( 7 mmol/mol IFCC ) ( P < 0.001 ) , was observed with glimepiride even though insulin doses had to be reduced in 23 patients ( median change 29 % , range 2-100 % ) .